Earnings Releases·Oct 29, 2026, 4:11 PM ET

Stryker — Third Quarter 2026 Earnings Summary

Consolidated net sales rose 7.7% year-over-year to $6.52 billion, while reported net earnings and diluted EPS declined 12.3% and 11.7% respectively to $753 million and $1.96 due to a $293 million goodwill impairment and $153 million in special charges; conversely, adjusted net earnings and diluted EPS increased 10.1% and 10.3% to $1.4 billion and $3.52.
Full-year 2026 guidance was updated to reflect organic net sales growth of 6.5% to 7.0% and adjusted diluted EPS of $14.80 to $14.90, with management citing strong underlying fundamentals despite the quarter falling short of internal expectations.
Strategic capital allocation included $1.0 billion in stock repurchases during the quarter and an additional $3.0 billion authorization in October 2026, alongside $1.012 billion in dividends paid over the nine-month period.
Segment performance was mixed, with MedSurg and Neurotechnology up 9.1% organically and Orthopaedics up 5.9%, driven by volume growth in Ortho Tech (+16.0%) and Trauma/Extremities (+5.5%), while Spinal Implants sales plummeted 45.4% in constant currency following a $9 million sale-related charge.